264 related articles for article (PubMed ID: 24507847)
1. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.
Giembycz MA; Newton R
Clin Chest Med; 2014 Mar; 35(1):203-17. PubMed ID: 24507847
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
[TBL] [Abstract][Full Text] [Related]
3. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
[TBL] [Abstract][Full Text] [Related]
4. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
5. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
6. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Wedzicha JA; Rabe KF; Martinez FJ; Bredenbröker D; Brose M; Goehring UM; Calverley PMA
Chest; 2013 May; 143(5):1302-1311. PubMed ID: 23117188
[TBL] [Abstract][Full Text] [Related]
8. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
[TBL] [Abstract][Full Text] [Related]
9. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast for COPD.
Izquierdo JL; Aparicio J
Drugs Today (Barc); 2010 Nov; 46(11):823-31. PubMed ID: 21225021
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
12. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
14. The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.
De Backer W; Vos W; Van Holsbeke C; Vinchurkar S; Claes R; Hufkens A; Parizel PM; Bedert L; De Backer J
Eur Respir J; 2014 Aug; 44(2):527-9. PubMed ID: 24791831
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
[TBL] [Abstract][Full Text] [Related]
16. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Sinopal'nikov AI
Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184
[TBL] [Abstract][Full Text] [Related]
17. Clinical Considerations for Roflumilast: A New Treatment for COPD.
Kelly Freeman ML
Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
[TBL] [Abstract][Full Text] [Related]
18. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
19. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
Martínez FJ
Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
[No Abstract] [Full Text] [Related]
20. Roflumilast: doubtful efficacy but clear harms in COPD.
Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
